KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Retained Earnings (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Retained Earnings data on record, last reported at $646.2 million in Q4 2025.

  • For Q4 2025, Retained Earnings fell 42.68% year-over-year to $646.2 million; the TTM value through Dec 2025 reached $646.2 million, down 42.68%, while the annual FY2025 figure was $646.2 million, 42.68% down from the prior year.
  • Retained Earnings reached $646.2 million in Q4 2025 per JAZZ's latest filing, up from -$569.9 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $1.3 billion in Q1 2021 and bottomed at -$1.1 billion in Q4 2022.
  • Average Retained Earnings over 5 years is $20.5 million, with a median of -$294.2 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: soared 717.95% in 2021, then crashed 479.27% in 2022.
  • A 5-year view of Retained Earnings shows it stood at $830.2 million in 2021, then tumbled by 235.57% to -$1.1 billion in 2022, then rose by 25.18% to -$842.1 million in 2023, then skyrocketed by 233.87% to $1.1 billion in 2024, then plummeted by 42.68% to $646.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $646.2 million in Q4 2025, -$569.9 million in Q3 2025, and -$485.8 million in Q2 2025.